In July 2019, another subsidiary of Mini-invasive Medical, “Xinmai Medical”, was listed on the Science and Technology Innovation Board.
According to Zhitong Financial, Wei Chuang Medical (00853.HK) plans to spin off its subsidiary MicroPort CardioFlow Medtech Corp (hereinafter referred to as “MicroPort CardioFlow”) to go public in Hong Kong this year, raising 200 million to 300 million US dollars. It has hired Citi and Xiaomo to arrange listing.
On January 5th, MicroPort Medical issued an announcement saying that it is considering the independent listing of MicroPort CardioFlow on a stock exchange. MicroPort CardioFlow and its affiliates are principally engaged in the development of structural cardiac devices for the treatment of heart valve disease.
Minimally Invasive Medical was established in Shanghai in 1998. It is an innovative high-end medical device company. Its main business is in the fields of cardiovascular intervention and structural cardiology, medical robotics and artificial intelligence. MicroPort Medical was listed on the main board of the Hong Kong Stock Exchange in 2010.
Due to the increasing market demand for medical devices and support from national policies, minimally invasive medical revenue has maintained steady growth from 2014 to 2018, achieving revenues of $ 355 million, $ 376 million, and $ 390 million USD, 444 million and 669 million.
Minimally invasive medical care has also recently gained capital favor. According to the data of the Stock Exchange, Minimise Capital has increased its capital holdings twice in the past month. Among them, on March 6, Gao Yong increased its holding of 47.734 million shares of MicroPort Medical at a price of HK $ 13.5149 per share, with a total amount of approximately HK $ 645 million. After the increase in shareholding, Gao Yi’s shareholding in minimally invasive medical care is about 6.61%.
In July 2019, another subsidiary of Minitrac Medical, “Xinmai Medical”, was listed on the science and technology board and raised 651 million yuan. Xinmai Medical is mainly engaged in the research and development, production and sales of aortic and peripheral vascular interventional medical devices.
As of press time, we have not yet received a response from Minimally Invasive Medical regarding the listing of the subsidiary.